Brandon Couillard
Stock Analyst at Wells Fargo
(3.63)
# 537
Out of 5,182 analysts
169
Total ratings
50%
Success rate
7.24%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHR Danaher | Maintains: Equal-Weight | $240 → $212 | $180.62 | +17.37% | 6 | Apr 22, 2026 | |
| BLLN BillionToOne | Maintains: Equal-Weight | $110 → $90 | $81.76 | +10.08% | 2 | Mar 5, 2026 | |
| NTRA Natera | Maintains: Equal-Weight | $205 → $215 | $204.39 | +5.19% | 4 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $175 → $165 | $115.62 | +42.71% | 26 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $190 → $180 | $118.29 | +52.17% | 4 | Feb 25, 2026 | |
| CDNA CareDx | Maintains: Equal-Weight | $18 → $21 | $21.85 | -3.89% | 5 | Feb 25, 2026 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $6.5 → $6 | $4.83 | +24.22% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $125 | $88.50 | +41.24% | 3 | Feb 20, 2026 | |
| AVTR Avantor | Maintains: Overweight | $16 → $14 | $7.97 | +75.66% | 6 | Feb 13, 2026 | |
| WAT Waters | Maintains: Equal-Weight | $415 → $355 | $299.79 | +18.42% | 8 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $155 | $66.17 | +134.25% | 7 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $76 | $55.11 | +37.91% | 3 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $83 → $94 | $98.28 | -4.35% | 5 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $107 → $110 | $86.80 | +26.73% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $635 → $675 | $468.04 | +44.22% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $1,450 | $1,274.70 | +13.75% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.68 | +22.28% | 2 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $55 | $36.53 | +50.56% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $287.29 | +18.35% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $291.46 | +16.65% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $184.70 | +40.77% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $77.20 | +3.63% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $26.77 | -14.08% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.57 | +405.84% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.01 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $2.65 | +315.09% | 2 | Oct 13, 2017 |
Danaher
Apr 22, 2026
Maintains: Equal-Weight
Price Target: $240 → $212
Current: $180.62
Upside: +17.37%
BillionToOne
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $110 → $90
Current: $81.76
Upside: +10.08%
Natera
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $205 → $215
Current: $204.39
Upside: +5.19%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $175 → $165
Current: $115.62
Upside: +42.71%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $190 → $180
Current: $118.29
Upside: +52.17%
CareDx
Feb 25, 2026
Maintains: Equal-Weight
Price Target: $18 → $21
Current: $21.85
Upside: -3.89%
Myriad Genetics
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $6.5 → $6
Current: $4.83
Upside: +24.22%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $125
Current: $88.50
Upside: +41.24%
Avantor
Feb 13, 2026
Maintains: Overweight
Price Target: $16 → $14
Current: $7.97
Upside: +75.66%
Waters
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $415 → $355
Current: $299.79
Upside: +18.42%
Feb 9, 2026
Upgrades: Overweight
Price Target: $155
Current: $66.17
Upside: +134.25%
Feb 6, 2026
Maintains: Overweight
Price Target: $70 → $76
Current: $55.11
Upside: +37.91%
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $83 → $94
Current: $98.28
Upside: -4.35%
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $107 → $110
Current: $86.80
Upside: +26.73%
Dec 15, 2025
Maintains: Overweight
Price Target: $635 → $675
Current: $468.04
Upside: +44.22%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1,400 → $1,450
Current: $1,274.70
Upside: +13.75%
Dec 15, 2025
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.68
Upside: +22.28%
Dec 15, 2025
Maintains: Overweight
Price Target: $48 → $55
Current: $36.53
Upside: +50.56%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $287.29
Upside: +18.35%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $291.46
Upside: +16.65%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $184.70
Upside: +40.77%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $77.20
Upside: +3.63%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $26.77
Upside: -14.08%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $2.57
Upside: +405.84%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $3.01
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $2.65
Upside: +315.09%